Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND.: Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma. METHODS.: By using Total Therapy 2 (TT2) clinical outcome data in 668 patients, whether sustained CR (SUS‐CR) was potentially a superior surrogate for survival than attaining CR status per se was evaluated. RESULTS.: Compared with not achieving CR (NON‐CR) and especially achieving and subsequently losing CR status (LOS‐CR) within a 3‐year landmark from treatment initiation, SUS‐CR was associated with highly superior postlandmark survival (P < .0001). These results were validated in 231 untreated patients enrolled in the predecessor trial, TT1 (hazard ratio [HR] = 0.54, P = .013) and in 1103 previously treated patients on other transplant protocols (HR = 0.49; P < .001). CONCLUSIONS.: In all 3 trial settings the survival benefit of SUS‐CR was independent of metaphase abnormalities as a dominant adverse parameter. Given its bleak prognosis despite high CR rates, SUS‐CR should be evaluated as a primary trial endpoint in high‐risk myeloma. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 1×
“Thus, raising CR frequency from less than 5% with standard melphalan-prednisone toward 50% with high-dose melphalan-based transplants was associated with an extension of median survival from less than 3 years to beyond 5 years.(4,5) For the reasons cited earlier, however, it is now apparent that CR per se is not a gua…”
Background
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
IMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601
Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 531
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M. A., Attal, M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-297325 · Cited by 314
Metadata
- Authors
- Barlogie, B., Anaissie, E., Haessler, J., van Rhee, F., Pineda‐Roman, M., Hollmig, K., Alsayed, Y., Epstein, J., Shaughnessy, J. D., & Crowley, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-07-08
- Volume
- 113
- Issue
- 2
- Pages
- 355-359
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1977194024
- Cited by
- 121
- References
- 2
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. https://app.cochat.ai/papers/10.1002/cncr.23546
- The paper
- Barlogie, B., Anaissie, E., Haessler, J., van Rhee, F., Pineda‐Roman, M., Hollmig, K., Alsayed, Y., Epstein, J., Shaughnessy, J. D., & Crowley, J. (2008). Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. https://doi.org/10.1002/cncr.23546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.